CIRCULATING CLONAL CELLS ARE PLENTYFUL IN PERIPHERAL BLOOD OF PATIENTS WITH MYELODYSPLASTIC SYNDROME: A COMPARISON OF THE PERCENTAGE OF CLONAL CELLS IN PB AND BM BY FLUORESCENT IN SITU HYBRIDIZATION
(Abstract release date: 05/19/16)
EHA Library. Lee D. 06/09/16; 132765; E1216
Prof. Dong Soon Lee
Contributions
Contributions
Abstract
Abstract: E1216
Type: Eposter Presentation
Background
Treatment response of MDS is determined by peripheral blood hemogram, bone marrow blast %, and cytogenetic results in BM. For the determination of treatment response, invasive BM study is required. We questioned whether the malignant cells are circulating or not in PB of patiens with MDS. We compared the percentage of clonal cells determined by fluorescent in situ hybridization (FISH) between PB and BM. If clonal cells are present in PB, monitoring of treatment response could be more easily accessible.
Aims
We aimed to investigate whether interphase fluorescence in situ hybridization (iFISH) clone size in peripheral blood correlate with bone marrow.
Methods
A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and +1/1q+) based on reported cytogenetic changes in Korean MDS patients, was performed in 98 patients with MDS at initial diagnosis. We performed corresponding FISH on peripheral blood in 28 patients in whom aberrant FISH results were observed in BM. The FISH probes used in the study were LSI EGR1 SpectrumOrange (5q31)/D5S23, D5S721 SpectrumGreen (5p15.2), LSI D7S522 SpectrumOrange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, LSI D20S108 SpectrumOrange (20q12) and LSI Trisomy 1q (1q25) SpectrumGreen (Abbott,Downers Grove, IL, USA).
Results
Among 98 patients diagnosed with MDS at initial diagnosis, 56.1% (55/98 patients) showed positive result by 5 kinds of FISH probes. In 82.1% of patients (23/28 patients), clonal cells was detectable in PB and the mean percentage was 30.4% (range from 2.5% to 80.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). However, the correlation of percentage value was high between PB and BM (r2=0.85); trisomy 8 (r2=0.85), 5q deletion (r2=0.85), 1q gain (r2=0.85) and 20q deletion (r2=0.85). In 3 patients with disease progression, percentage of clonal cells showed signficant interval change.
Conclusion
Our results suggest FISH monitoring of peripheral blood can be used as a potential candidate for monitoring tool of treatment response in MDS.
Session topic: E-poster
Keyword(s): Monitor, Peripheral blood progenitor cell, Treatment
Type: Eposter Presentation
Background
Treatment response of MDS is determined by peripheral blood hemogram, bone marrow blast %, and cytogenetic results in BM. For the determination of treatment response, invasive BM study is required. We questioned whether the malignant cells are circulating or not in PB of patiens with MDS. We compared the percentage of clonal cells determined by fluorescent in situ hybridization (FISH) between PB and BM. If clonal cells are present in PB, monitoring of treatment response could be more easily accessible.
Aims
We aimed to investigate whether interphase fluorescence in situ hybridization (iFISH) clone size in peripheral blood correlate with bone marrow.
Methods
A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and +1/1q+) based on reported cytogenetic changes in Korean MDS patients, was performed in 98 patients with MDS at initial diagnosis. We performed corresponding FISH on peripheral blood in 28 patients in whom aberrant FISH results were observed in BM. The FISH probes used in the study were LSI EGR1 SpectrumOrange (5q31)/D5S23, D5S721 SpectrumGreen (5p15.2), LSI D7S522 SpectrumOrange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, LSI D20S108 SpectrumOrange (20q12) and LSI Trisomy 1q (1q25) SpectrumGreen (Abbott,Downers Grove, IL, USA).
Results
Among 98 patients diagnosed with MDS at initial diagnosis, 56.1% (55/98 patients) showed positive result by 5 kinds of FISH probes. In 82.1% of patients (23/28 patients), clonal cells was detectable in PB and the mean percentage was 30.4% (range from 2.5% to 80.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). However, the correlation of percentage value was high between PB and BM (r2=0.85); trisomy 8 (r2=0.85), 5q deletion (r2=0.85), 1q gain (r2=0.85) and 20q deletion (r2=0.85). In 3 patients with disease progression, percentage of clonal cells showed signficant interval change.
Conclusion
Our results suggest FISH monitoring of peripheral blood can be used as a potential candidate for monitoring tool of treatment response in MDS.
Session topic: E-poster
Keyword(s): Monitor, Peripheral blood progenitor cell, Treatment
Abstract: E1216
Type: Eposter Presentation
Background
Treatment response of MDS is determined by peripheral blood hemogram, bone marrow blast %, and cytogenetic results in BM. For the determination of treatment response, invasive BM study is required. We questioned whether the malignant cells are circulating or not in PB of patiens with MDS. We compared the percentage of clonal cells determined by fluorescent in situ hybridization (FISH) between PB and BM. If clonal cells are present in PB, monitoring of treatment response could be more easily accessible.
Aims
We aimed to investigate whether interphase fluorescence in situ hybridization (iFISH) clone size in peripheral blood correlate with bone marrow.
Methods
A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and +1/1q+) based on reported cytogenetic changes in Korean MDS patients, was performed in 98 patients with MDS at initial diagnosis. We performed corresponding FISH on peripheral blood in 28 patients in whom aberrant FISH results were observed in BM. The FISH probes used in the study were LSI EGR1 SpectrumOrange (5q31)/D5S23, D5S721 SpectrumGreen (5p15.2), LSI D7S522 SpectrumOrange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, LSI D20S108 SpectrumOrange (20q12) and LSI Trisomy 1q (1q25) SpectrumGreen (Abbott,Downers Grove, IL, USA).
Results
Among 98 patients diagnosed with MDS at initial diagnosis, 56.1% (55/98 patients) showed positive result by 5 kinds of FISH probes. In 82.1% of patients (23/28 patients), clonal cells was detectable in PB and the mean percentage was 30.4% (range from 2.5% to 80.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). However, the correlation of percentage value was high between PB and BM (r2=0.85); trisomy 8 (r2=0.85), 5q deletion (r2=0.85), 1q gain (r2=0.85) and 20q deletion (r2=0.85). In 3 patients with disease progression, percentage of clonal cells showed signficant interval change.
Conclusion
Our results suggest FISH monitoring of peripheral blood can be used as a potential candidate for monitoring tool of treatment response in MDS.
Session topic: E-poster
Keyword(s): Monitor, Peripheral blood progenitor cell, Treatment
Type: Eposter Presentation
Background
Treatment response of MDS is determined by peripheral blood hemogram, bone marrow blast %, and cytogenetic results in BM. For the determination of treatment response, invasive BM study is required. We questioned whether the malignant cells are circulating or not in PB of patiens with MDS. We compared the percentage of clonal cells determined by fluorescent in situ hybridization (FISH) between PB and BM. If clonal cells are present in PB, monitoring of treatment response could be more easily accessible.
Aims
We aimed to investigate whether interphase fluorescence in situ hybridization (iFISH) clone size in peripheral blood correlate with bone marrow.
Methods
A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and +1/1q+) based on reported cytogenetic changes in Korean MDS patients, was performed in 98 patients with MDS at initial diagnosis. We performed corresponding FISH on peripheral blood in 28 patients in whom aberrant FISH results were observed in BM. The FISH probes used in the study were LSI EGR1 SpectrumOrange (5q31)/D5S23, D5S721 SpectrumGreen (5p15.2), LSI D7S522 SpectrumOrange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, LSI D20S108 SpectrumOrange (20q12) and LSI Trisomy 1q (1q25) SpectrumGreen (Abbott,Downers Grove, IL, USA).
Results
Among 98 patients diagnosed with MDS at initial diagnosis, 56.1% (55/98 patients) showed positive result by 5 kinds of FISH probes. In 82.1% of patients (23/28 patients), clonal cells was detectable in PB and the mean percentage was 30.4% (range from 2.5% to 80.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). The proportion of FISH-positive cells in PB was lower compared with the those in BM, and the mean percent difference between BM and PB was 30.5% (range from -11.2% to 45.0%). However, the correlation of percentage value was high between PB and BM (r2=0.85); trisomy 8 (r2=0.85), 5q deletion (r2=0.85), 1q gain (r2=0.85) and 20q deletion (r2=0.85). In 3 patients with disease progression, percentage of clonal cells showed signficant interval change.
Conclusion
Our results suggest FISH monitoring of peripheral blood can be used as a potential candidate for monitoring tool of treatment response in MDS.
Session topic: E-poster
Keyword(s): Monitor, Peripheral blood progenitor cell, Treatment
{{ help_message }}
{{filter}}